Dergiler / Medicine Science / 2021 / Cilt: 10 - Sayı: 2

Clinical findings and immunophenotypic profile of plasma cell leukemia: a retrospective study in a comprehensive cancer center in Turkey

Sayfa
455–461
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Co-expression of CD38 and CD138 in identifying PCs with MFC may be considered the best combination and leads to early diagnosis within hours and appropriate treatment in patients with PCL.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Plasma cell leukemia (PCL) is a rare (1-2 %) aggressive plasma cell dyscrasia (PCD) with a poor prognosis and characterized by the presence of more than 20% circulating plasma cells (PCs).
📊
Temel Bulgular & Veri:A total of 512 patients were investigated for PCD in our hospital between 2011-2019.
💡
Sonuç & Katkı:Co-expression of CD38 and CD138 in identifying PCs with MFC may be considered the best combination and leads to early diagnosis within hours and appropriate treatment in patients with PCL.
🔬Tür:Araştırma Makalesi
📍Kapsam:2011-2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Plasma cell leukemia (PCL) is a rare (1-2 %) aggressive plasma cell dyscrasia (PCD) with a poor prognosis and characterized by the presence of more than 20% circulating plasma cells (PCs). Multicolor Flowcytometry is used for differentiating PCs in PCL. In this study, we aimed to compare the clinical, laboratory findings and immunophenotypic profiles of patients with PCL. A total of 512 patients were investigated for PCD in our hospital between 2011-2019. The immunophenotypic profile (including, CD27, CD28, CD38, CD138, CD45, CD117, CD19, CD20, CD56, CD33, CD81, and ckappa /clambda,) were evaluated retrospectively. The clinical findings, pathology reports, immunofixation electrophoresis and MFC results of three patients with PCL were reevaluated using 6 color multiparametric flow cytometry (MFC). Only three patients were diagnosed as PCL. PCs population defined by the co-expression of CD38 and CD138 was observed as 50%, 53%, 60%, respectively. Expression of each CD56, CD117, CD20, CD45 was seen in individual cases. CD19 was negative in all cases. Cytoplasmic kappa light chain expression was detected only in one case. Two of the cases were primary and the other was secondary PCL. Bortezomib-based treatment was initiated. Overall survival of primary PCL cases were 24 months and 6 months, whereas secondary PCL was four months. Co-expression of CD38 and CD138 in identifying PCs with MFC may be considered the best combination and leads to early diagnosis within hours and appropriate treatment in patients with PCL.

🔖

Bu Makaleye Atıf Yap

Basci, S., Altuntas, F., Dal, M. S., Yilmaz, F. M., Bakirtas, M., Ozcan, N., Ozcan, E., Cakar, M. K. (2022). Clinical findings and immunophenotypic profile of plasma cell leukemia: a retrospective study in a comprehensive cancer center in Turkey. Medicine Science, Cilt: 10 - Sayı: 2, 455–461. https://ajindex.com/articles/575883

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. De Larrea CF, Kyle RA, Durie BG, et al. PCs leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780-91. Group IMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-57.
  2. Ramsingh G, Mehan P, Luo J, et al. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer. 2009;115:5734-9.
  3. Royer B, Minvielle S, Diouf M, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016;34:2125-32. Gonsalves WI. Primary plasma cell leukemia: a practical approach to diagnosis and clinical management. AJHO. 2017;13:21-5.
  4. Woodruff R, Malpas J, Paxton A, et al. Plasma cell leukemia (PCL): A report on 15 patients. Blood. 1978;52:839-45.
  5. Garcıa-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-7.
  6. Tiedemann R, Gonzalez-Paz N, Kyle R, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22:1044-52.
  7. Witzig TE, Gertz M, Lust JA, et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood. 1996;88:1780-7.
  8. Granell M, Calvo X, Garcia-Guiñón A, et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017;102:1099-104.
  9. Ravi P, Kumar SK, Roeker L, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J. 2018;8:1-6.
  10. Perez-Andres M, Santiago M, Almeida J, et al. Immunophenotypic approach to the identification and characterization of clonal plasma cells from patients with monoclonal gammopathies. J Biol Regul Homeost Agents. 2004;18:391-8.
  11. Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93:431-8. Flores‐Montero J, de Tute R, Paiva B, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody